Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J. L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D., Choueiri, T. K., Necchi, A., Gerritsen, W. R., Gurney, H., Quinn, D. I., Culine, S., Sternberg, C. N., Jensen, E., Frenkl, T., Perini, R. F., & Bajorin, D. (n.d.). 901PImpact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045. Annals of oncology, 29, . http://access.bl.uk/ark:/81055/vdc_100095513869.0x000036